Immune Design Corporation Announces Upcoming Financial Results And Immuno-oncology Conference Presentation

SEATTLE and SOUTH SAN FRANCISCO, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year-end 2014 financial results at the closing of U.S. financial markets on Tuesday, March 31, 2015. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 844-831-3023for domestic callers and 920-663-6275for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for ninety days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 11929185.

In addition, Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Maidstone Life Sciences 5^th Annual Conference “Cancer Immunotherapy” on Thursday, March 26, 2015 at 9:30 am Eastern Time in New York. A live webcast of the presentation will be available online from the investor relations page of the company’s corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design’s three on-going immuno-oncology clinical programs are the product of its two synergistic discovery platforms, ZVex^TM and GLAAS^TM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

CONTACT: Media Contact Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219 Investor Contact Shari Annes Annes Associates sannes@annesassociates.com 650-888-0902

Help employers find you! Check out all the jobs and post your resume.